文献速递临床试验与 GCP

婴儿反流试验:关于婴儿胃食管反流病治疗的多中心随机对照试验研究方案

Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of gastroesophageal reflux disease in infants.
PubMed 文献 · Trials · 2026-01-29

本研究为多中心随机安慰剂对照试验方案,计划在丹麦南部3个儿科中心纳入96名临床诊断胃食管反流病的婴儿,随机分为三组:牛奶蛋白回避饮食组、质子泵抑制剂组和安慰剂对照组。干预4周,主要结局为反流发作次数减少,次要结局包括体重增长和胃食管反流病相关症状减少,症状由家长通过数字应用报告,并量化所有参与者的牛奶蛋白特异性IgE。

要点

  • 纳入96名临床诊断胃食管反流病的婴儿,随机分为饮食组、质子泵抑制剂组和安慰剂对照组。
  • 干预4周,主要结局为反流发作次数减少,次要结局包括体重增长和胃食管反流病相关症状减少。
  • 饮食组中响应者将接受口服牛奶激发试验以确认牛奶蛋白过敏。

核心结论

  • 该试验旨在为牛奶蛋白回避饮食和质子泵抑制剂治疗婴儿胃食管反流病的疗效提供证据。
  • 两种干预均与对照组比较,以确保任何改善超过症状随时间自然缓解的过程。
  • 研究结果将为指导临床实践和改善婴儿胃食管反流病治疗策略提供见解。

研究设计与样本

  • 多中心、随机、安慰剂对照试验方案,在丹麦南部3个儿科中心纳入96名临床诊断胃食管反流病的婴儿。
  • 符合条件的参与者随机分配至三个平行组:牛奶蛋白回避饮食组、质子泵抑制剂组和接受安慰剂药物的对照组。
  • 质子泵抑制剂组和对照组设盲,并继续含牛奶蛋白的饮食;干预期为4周。
  • 主要结局为反流发作次数的减少;次要结局包括体重增长和胃食管反流病相关症状的减少。
  • 症状数据由家长通过数字应用报告,并量化所有参与者的牛奶蛋白特异性IgE;饮食组中响应者接受口服牛奶激发试验以确认牛奶蛋白过敏。

关键数值与推荐

  • 当前国际指南推荐在开始质子泵抑制剂药物治疗前尝试牛奶蛋白回避饮食。
  • 主要结局为反流发作次数的减少;次要结局包括体重增长和胃食管反流病相关症状的减少。
  • 干预期为4周。

临床怎么用

  • 当前国际指南推荐在开始质子泵抑制剂药物治疗前尝试牛奶蛋白回避饮食。
  • 作者认为该试验结果将为指导临床实践和改善婴儿胃食管反流病治疗策略提供见解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gastroesophageal reflux disease (GERD) is a common condition in infants below 1 year of age. Symptoms include frequent regurgitation, failure to thrive, food refusal, irritability, and back arching. While many infants experience some degree of physiological reflux, persistent or severe symptoms may indicate GERD. One important underlying cause of GERD in infants is allergy to cow's milk protein. Current international guidelines recommend a trial of a cow's milk protein-free diet prior to initiating medical therapy with a proton-pump inhibitor. However, the efficacy of both the diet and the medication remains insufficiently studied. With only a few randomized trials available, further evidence is needed to ensure infants receive the most appropriate treatment. METHODS: This protocol describes a multicentre, randomized placebo-controlled trial, enrolling 96 infants with a clinical diagnosis of GERD at 3 paediatric centres in Southern Denmark. Eligible participants will be randomly assigned to one of three parallel groups: (1) A diet group receiving a cow's milk protein-free diet, (2) a medicine group treated with a proton-pump inhibitor, and (3) a control group receiving a placebo medicine. Both the PPI group and the control group will be blinded to the allocation and will continue a diet containing cow's milk protein. The intervention period is 4 weeks. The primary outcome is the reduction in the number of regurgitation episodes. Secondary outcomes include weight gain and reduction in GERD-related symptoms. Symptom data will be reported by parents using a digital application, and specific IgE to cow's milk protein will be quantified in all participants. Infants in the diet group who respond positively will undergo an oral milk challenge to confirm allergy to cow's milk protein. DISCUSSION: This trial is designed to provide evidence on the efficacy of a cow's milk protein-free diet and proton-pump inhibitor therapy for infant GERD. Both interventions are evaluated against a control group, ensuring that any improvement exceeds the natural course of symptom resolution over time. The findings will provide valuable insights to guide clinical practice and enhance treatment strategies for infant GERD, a condition with a substantial impact on infant health and family well-being. PROSPECTIVE TRIAL REGISTRATION: ClinicalTrials.gov NCT06255886. Registered on February 13, 2024. CLINICALTRIALS: eu EU-CT: 2022-502770-16-00. Registered on November 4, 2024.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Barkholt NK, Dalby K, Mogensen CB, et al. Infant Reflux Trial: study protocol for a multicentre randomized controlled trial on the treatment of gastroesophageal reflux disease in infants. Trials. 2026. PMID: 41612404. doi:10.1186/s13063-026-09477-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。